ACULYS serves patients’ unmet needs through improved access to innovative CNS medicines.
ACULYS is a private biopharma company focused on the development and commercialization of innovative, best-in-class therapeutics. We specialize in CNS and are committed to helping patients in Japan who are suffering from debilitating neurologic diseases improve their quality of life.
THE PROBLEM
Narcolepsy is a rare neurologic sleep disorder with its primary symptom being excessive daytime sleepiness, which is unfortunately a common symptom of other disorders beyond narcolepsy. This combined with the fact that narcolepsy often occurs together with other disorders and a low level public awareness of disease has resulted in a low rate of diagnosis of narcolepsy in Japan.
Pharmacological therapies for hypersomnias in Japan are limited, and we believe there is significant room to improve in treatments in terms of efficacy and safety.
Neuropsychiatric sequelae of the disease include memory loss, poor concentration, depression and anxiety, often resulting in psycho-social impairments on relationships, academic performance, professional success and leisure activities.
Estimates of economic burden of narcolepsy is over 136 billion USD annually in Japan (RAND Corp. report 2016).
THE SOLUTION
Aculys is developing a new medicine in Japan for patients suffering from Narcolepsy and other sleep disorders. We are also continuously exploring opportunities to discover other innovations to address the unmet needs of patients.
Aculys works with patients, their families, advocacy groups and healthcare providers to increase awareness of narcolepsy, aimed at increasing the rates of diagnosis and treatment in Japan. Aculys’ vision is to improve the lives of patients through quality diagnosis, treatment and follow-up.
Aculys is a biopharmaceutical company grounded not only in its excellence of pharmaceutical science but equally in data science. We are committed to maximizing the potential of real-world data to generate and advance real-world evidence through the integration of digital devices and AI.
– Initiating digital transformation (DX) in clinical trial and joint research utilizing real-world data – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo; Representative Director
– Introducing digital transformation (DX) for monitoring work and reducing new drug development costs – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo, President and
– a fact-finding survey of patients with sleep disorders to be conducted as a first step – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo,